An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Overall Survival (OS)

Overall survival is defined as the time from randomization to the date of death from any cause. For subjects that are alive, their survival time was censored at the date of last contact date (or "last known alive date"). Overall survival was censored at the date of randomization for subjects who were randomized but had no follow-up.

Time frame: From randomization to the date of death (up to approximately 60 months)

Overall Survival Rates at 12-, 24-, and 36-months

Overall survival rate is defined as the percentage of participants who are alive at 1, 2 and 3 years following randomization

Time frame: At 12-, 24- and 36-months post first dose.